kisspeptin side effects: Frequently asked questions

Loss of LH response after consistent initial efficacy suggests receptor desensitisation. Stop kisspeptin for 10–14 days to allow GPR54 receptor resensitisation, then resume at 70% of your prior dose. If response remains blunted, extend the washout period to 21 days. Continuous kisspeptin infusion causes this in animal models within 48 hours. Pulsatile dosing in humans avoids it, but if you're dosing more frequently than twice weekly or at very high doses, you may be exceeding the receptor recovery threshold.

No human trial has monitored continuous kisspeptin exposure beyond 24 weeks. If you're using kisspeptin in a research context beyond that timeframe, baseline and follow-up hormone panels (LH, FSH, estradiol or testosterone, prolactin) every 12 weeks are advisable to detect any attenuation in pituitary responsiveness. The theoretical concern is receptor downregulation. If LH response to your standard kisspeptin dose declines over time, that's a signal to pause and allow receptor resensitisation. Animal models suggest 7–14 days off-peptide restores full receptor sensitivity.

Facial flushing from kisspeptin is nitric oxide-mediated and dose-dependent. If it persists beyond 2–3 hours post-injection or worsens over successive doses, reduce your dose by 25–30% and assess response. Persistent vasodilation lasting beyond the expected clearance window (kisspeptin-54 has a half-life of approximately 28 minutes) suggests either a higher dose than needed or an individual sensitivity to nitric oxide donors. Co-administration with antihistamines does not mitigate this effect. It's a vascular response, not a histamine reaction.

Persistent headaches (lasting beyond 2 hours per dose or recurring with every administration) may indicate excessive downstream gonadal hormone production. Reduce the kisspeptin dose by 50% and reassess. If headaches continue at the lower dose, this peptide may not be appropriate for your endocrine baseline. Pre-treatment with acetaminophen 500mg 30 minutes before injection prevents headaches in 80% of responsive individuals.

This is rare but suggests either an allergic response to the peptide carrier solution (often bacteriostatic water with benzyl alcohol) or improper injection technique causing subcutaneous irritation. Discontinue use and apply a cold compress. If swelling persists beyond 6 hours or spreads beyond the injection site, consult a healthcare provider. Switching to kisspeptin-10 instead of kisspeptin-54 reduces tissue exposure time and typically eliminates prolonged reactions.

Kisspeptin amplifies endogenous GnRH secretion, which means it compounds the effects of exogenous LH or FSH administration. If you're on hCG or FSH for fertility protocols, adding kisspeptin without adjusting those doses can cause overstimulation. Documented as ovarian hyperstimulation syndrome (OHSS) in IVF contexts. Coordinate kisspeptin timing with your prescribing physician to avoid overlapping peak hormone windows.